Stockscreener 앱 받기
455.48
0.39%
-1.78
전일 마감가:
$457.26
열려 있는:
$457.78
하루 거래량:
911.14K
Relative Volume:
0.62
시가총액:
$115.56B
수익:
$11.74B
순이익/손실:
$3.68B
주가수익비율:
32.10
EPS:
14.1888
순현금흐름:
$3.34B
1주 성능:
+5.04%
1개월 성능:
+9.23%
6개월 성능:
+2.63%
1년 성능:
-0.97%
1일 변동 폭
$454.45
$462.00
1주일 범위
$423.45
$463.85
52주 변동 폭
$362.50
$519.68
버텍스 파마슈티컬 Stock (VRTX) Company Profile
명칭
Vertex Pharmaceuticals Inc
전화
(617) 341-6393
주소
50 NORTHERN AVENUE, BOSTON, MA
VRTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
버텍스 파마슈티컬 Stock (VRTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-09-25 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | 개시 | Raymond James | Mkt Perform |
| 2025-08-06 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-02-12 | 업그레이드 | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | 업그레이드 | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | 재확인 | H.C. Wainwright | Buy |
| 2024-12-19 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Perform |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-08-05 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-06-27 | 개시 | Redburn Atlantic | Buy |
| 2024-04-11 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2024-02-06 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-02-02 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-01-31 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | 다운그레이드 | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | 개시 | William Blair | Outperform |
| 2023-05-04 | 재개 | Piper Sandler | Overweight |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-01-18 | 개시 | Canaccord Genuity | Hold |
| 2023-01-17 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-01 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-05-06 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | 재확인 | JP Morgan | Overweight |
| 2022-01-27 | 재확인 | Morgan Stanley | Underweight |
| 2022-01-27 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-01-27 | 재확인 | Stifel | Hold |
| 2022-01-27 | 재확인 | Wolfe Research | Outperform |
| 2022-01-20 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-11-19 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | 재개 | Wolfe Research | Outperform |
| 2021-07-01 | 개시 | Raymond James | Mkt Perform |
| 2021-06-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-30 | 개시 | Daiwa Securities | Outperform |
| 2020-11-30 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | 개시 | Bernstein | Outperform |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-07-31 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-31 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-09-03 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-08-01 | 다운그레이드 | Needham | Buy → Hold |
| 2019-05-23 | 재개 | Citigroup | Buy |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-12 | 개시 | Evercore ISI | In-line |
| 2019-03-26 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | 다운그레이드 | Maxim Group | Buy → Hold |
모두보기
버텍스 파마슈티컬 주식(VRTX)의 최신 뉴스
First Trust Advisors LP Purchases 143,084 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Insider Sell: WAGNER CHARLES F JR Sells 14,000 Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Vertex Pharma executive chairman sells $28.6m in stock - Investing.com India
Vertex Pharmaceuticals Insider Sold Shares Worth $2,024,955, According to a Recent SEC Filing - marketscreener.com
VP Tatsis Sells 4,500 ($2M) Of Vertex Pharmaceuticals Inc [VRTX] - TradingView
Vertex Pharmaceuticals EVP Sells Shares Under Trading Plan - TradingView
VRTX Analyst Rating Update: Morgan Stanley Raises Price Target | VRTX Stock News - GuruFocus
Morgan Stanley Adjusts PT on Vertex Pharmaceuticals to $564 From $516, Maintains Overweight Rating - marketscreener.com
Can Vertex Pharmaceuticals Incorporated (VX1) stock sustain breakout momentumWeekly Trade Report & Technical Confirmation Trade Alerts - Newser
Why Vertex Pharmaceuticals Incorporated stock appeals to dividend seekers2025 Market Overview & Expert Curated Trade Ideas - Newser
Amundi Has $517.92 Million Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
1 Reason I'll Never Sell Vertex Pharmaceuticals Stock - Finviz
Citi Healthcare In Brief: Launch Trajectories Under Scrutiny - Citeline News & Insights
1 Reason I'll Never Sell Vertex Pharmaceuticals Stock - The Motley Fool
Is Vertex Pharmaceuticals Incorporated stock resilient to inflationWeekly Stock Report & Technical Confirmation Trade Alerts - Newser
Why Analysts See Vertex Pharmaceuticals Story Shifting With New Pipeline Momentum and Valuation Debates - Yahoo Finance
Harding Loevner Global Equity’s Views on Vertex Pharmaceuticals Incorporated (VRTX) - Insider Monkey
Vertex Pharmaceuticals (NASDAQ:VRTX) Raised to Overweight at Morgan Stanley - MarketBeat
Westerkirk Capital Inc. Acquires New Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals (VRTX): Assessing Valuation After Recent Multi-Month Share Price Gains - Yahoo Finance
Invesco Ltd. Raises Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Why Vertex Pharmaceuticals Incorporated (VX1) stock stays resilientPortfolio Performance Summary & Smart Money Movement Tracker - Newser
CW Advisors LLC Buys 4,801 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Fisher Asset Management LLC Has $11.47 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Published on: 2025-12-03 23:31:46 - Newser
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MSN
Check Out What Whales Are Doing With VRTX - Benzinga
Vertex Pharmaceuticals (VRTX) Upgraded by Morgan Stanley with Op - GuruFocus
Why Vertex Pharmaceuticals (VRTX) Stock Is Up Today - Finviz
Vertex upgraded at Morgan Stanley on kidney pipeline - Seeking Alpha
Vertex Wins Wall Street Back With Kidney Drug Bets - Finimize
Why Is Vertex (VRTX) Up 2.7% Since Last Earnings Report? - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Receives Rating Upgrade from Morgan Stanley | VRTX Stock News - GuruFocus
Vertex Up 9.2% in 3 Months: Should You Buy, Sell or Hold the Stock? - Finviz
Transcript : Vertex Pharmaceuticals Incorporated Presents at Citi Annual Global Healthcare Conference 2025, Dec-03-2025 09 - marketscreener.com
Is Vertex Pharmaceuticals Incorporated (VX1) stock a buy on weaknessQuarterly Market Summary & Stepwise Swing Trade Plans - Newser
Morgan Stanley upgrades Vertex stock to Overweight on kidney pipeline potential - Investing.com
Morgan Stanley Upgrades Vertex Pharmaceuticals to Overweight From Equalweight, Adjusts PT to $516 From $438 - MarketScreener
Published on: 2025-12-02 23:32:41 - Newser
Akeso’s Goals Beyond Ivonescimab: ‘We Can Hit Vertex And Regeneron-Level Innovation’ - Citeline News & Insights
Schroder Investment Management Group Reduces Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock - sharewise.com
BLI Banque de Luxembourg Investments Purchases Shares of 6,500 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
West Family Investments Inc. Buys 1,015 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
New York State Common Retirement Fund Cuts Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Quadrature Capital Ltd Buys Shares of 17,913 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Level Four Advisory Services LLC Sells 985 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Johnson Financial Group Inc. Has $189,000 Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Is Vertex Pharmaceuticals Incorporated stock ready for breakoutEarnings Growth Report & Low Risk High Reward Ideas - moha.gov.vn
Is Vertex Pharmaceuticals Stock Underperforming the Nasdaq? - MSN
Edgewood Management LLC Trims Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
버텍스 파마슈티컬 (VRTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.62%
자본화:
|
볼륨(24시간):